The Interleukin (IL)-1R1 pathway is a critical negative regulator of PyMT-mediated mammary tumorigenesis and pulmonary metastasis

References

• Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136:E359-86; PMID:25220842; http://dx.doi.org/10.1002/ijc.29210
   PubMed Web of Science ®Google Scholar
• Hon JD, Singh B, Sahin A, Du G, Wang J, Wang VY, Deng FM, Zhang DY, Monaco ME, Lee P. Breast cancer molecular subtypes: from TNBC to QNBC. Am J Cancer Res 2016; 6:1864-72; PMID:27725895
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, Panel members. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22:1736-47; PMID:21709140; http://dx.doi.org/10.1093/annonc/mdr304
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300; PMID:20610543; http://dx.doi.org/10.3322/caac.20073
   PubMed Web of Science ®Google Scholar
• Hoos A. Development of immuno-oncology drugs – from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov 2016; 15:235-47; PMID:26965203; http://dx.doi.org/10.1038/nrd.2015.35
   PubMed Web of Science ®Google Scholar
• Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y, Voronov E. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 2006; 25:387-408; PMID:17043764; http://dx.doi.org/10.1007/s10555-006-9004-4
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev 2010; 29:317-29; PMID:20422276; http://dx.doi.org/10.1007/s10555-010-9229-0
   PubMed Web of Science ®Google Scholar
• Dinarello CA. An expanding role for interleukin-1 blockade from gout to cancer. Mol Med 2014; 20 Suppl 1:S43-58; PMID:25549233; http://dx.doi.org/10.2119/molmed.2014.00232
   PubMedGoogle Scholar
• Zitvogel L, Kepp O, Galluzzi L, Kroemer G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol 2012; 13:343-51; PMID:22430787; http://dx.doi.org/10.1038/ni.2224
   PubMed Web of Science ®Google Scholar
• Di Paolo NC, Shayakhmetov DM. Interleukin 1alpha and the inflammatory process. Nat Immunol 2016; 17:906-13; PMID:27434011; http://dx.doi.org/10.1038/ni.3503
   PubMed Web of Science ®Google Scholar
• Auron PE, Webb AC, Rosenwasser LJ, Mucci SF, Rich A, Wolff SM, Dinarello CA. Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci USA 1984; 81:7907-11; PMID:6083565; http://dx.doi.org/10.1073/pnas.81.24.7907
   PubMed Web of Science ®Google Scholar
• Lomedico PT, Gubler U, Hellmann CP, Dukovich M, Giri JG, Pan YC, Collier K, Semionow R, Chua AO, Mizel SB. Cloning and expression of murine interleukin-1 cDNA in Escherichia coli. Nature 1984; 312:458-62; PMID:6209582; http://dx.doi.org/10.1038/312458a0
   PubMed Web of Science ®Google Scholar
• March CJ, Mosley B, Larsen A, Cerretti DP, Braedt G, Price V, Gillis S, Henney CS, Kronheim SR, Grabstein K et al. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature 1985; 315:641-7; PMID:2989698; http://dx.doi.org/10.1038/315641a0
   PubMed Web of Science ®Google Scholar
• Kim B, Lee Y, Kim E, Kwak A, Ryoo S, Bae SH, Azam T, Kim S, Dinarello CA. The Interleukin-1α precursor is biologically active and is likely a key alarmin in the IL-1 family of cytokines. Front Immunol 2013; 4:391; PMID:24312098; http://dx.doi.org/10.3389/fimmu.2013.00391
   PubMed Web of Science ®Google Scholar
• He Y, Hara H, Nunez G. Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem Sci 2016; 41(12):1012-21; PMID:27669650; http://dx.doi.org/10.1016/j.tibs.2016.09.002
   PubMed Web of Science ®Google Scholar
• Afonina IS, Tynan GA, Logue SE, Cullen SP, Bots M, Luthi AU, Reeves EP, McElvaney NG, Medema JP, Lavelle EC et al. Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1alpha. Mol Cell 2011; 44:265-78; PMID:22017873; http://dx.doi.org/10.1016/j.molcel.2011.07.037
   PubMed Web of Science ®Google Scholar
• Kurt-Jones EA, Beller DI, Mizel SB, Unanue ER. Identification of a membrane-associated interleukin 1 in macrophages. Proc Natl Acad Sci USA 1985; 82:1204-8; PMID:3919388; http://dx.doi.org/10.1073/pnas.82.4.1204
   PubMed Web of Science ®Google Scholar
• Wessendorf JH, Garfinkel S, Zhan X, Brown S, Maciag T. Identification of a nuclear localization sequence within the structure of the human interleukin-1 alpha precursor. J Biol Chem 1993; 268:22100-4; PMID:8408068
   PubMed Web of Science ®Google Scholar
• Apte RN, Dvorkin T, Song X, Fima E, Krelin Y, Yulevitch A, Gurfinkel R, Werman A, White RM, Argov S et al. Opposing effects of IL-1 alpha and IL-1 beta on malignancy patterns. Tumor cell-associated IL-1 alpha potentiates anti-tumor immune responses and tumor regression, whereas IL-1 beta potentiates invasiveness. Adv Exp Med Biol 2000; 479:277-88; PMID:10897428
   PubMed Web of Science ®Google Scholar
• Song X, Voronov E, Dvorkin T, Fima E, Cagnano E, Benharroch D, Shendler Y, Bjorkdahl O, Segal S, Dinarello CA et al. Differential effects of IL-1 alpha and IL-1 beta on tumorigenicity patterns and invasiveness. J Immunol 2003; 171:6448-56; PMID:14662844; http://dx.doi.org/10.4049/jimmunol.171.12.6448
   PubMed Web of Science ®Google Scholar
• Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, Dinarello CA, Apte RN. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 2003; 100:2645-50; PMID:12598651; http://dx.doi.org/10.1073/pnas.0437939100
   PubMed Web of Science ®Google Scholar
• Krelin Y, Voronov E, Dotan S, Elkabets M, Reich E, Fogel M, Huszar M, Iwakura Y, Segal S, Dinarello CA et al. Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res 2007; 67:1062-71; PMID:17283139; http://dx.doi.org/10.1158/0008-5472.CAN-06-2956
   PubMed Web of Science ®Google Scholar
• Murphy JE, Morales RE, Scott J, Kupper TS. IL-1 alpha, innate immunity, and skin carcinogenesis: the effect of constitutive expression of IL-1 alpha in epidermis on chemical carcinogenesis. J Immunol 2003; 170:5697-703; PMID:12759452; http://dx.doi.org/10.4049/jimmunol.170.11.5697
   PubMed Web of Science ®Google Scholar
• Giavazzi R, Garofalo A, Bani MR, Abbate M, Ghezzi P, Boraschi D, Mantovani A, Dejana E. Interleukin 1-induced augmentation of experimental metastases from a human melanoma in nude mice. Cancer Res 1990; 50:4771-5; PMID:2196116
   PubMed Web of Science ®Google Scholar
• Lauri D, Bertomeu MC, Orr FW, Bastida E, Sauder D, Buchanan MR. Interleukin-1 increases tumor cell adhesion to endothelial cells through an RGD dependent mechanism: in vitro and in vivo studies. Clin Exp Metastasis 1990; 8:27-32; PMID:2293911; http://dx.doi.org/10.1007/BF00155590
   PubMed Web of Science ®Google Scholar
• Lewis AM, Varghese S, Xu H, Alexander HR. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med 2006; 4:48; PMID:17096856; http://dx.doi.org/10.1186/1479-5876-4-48
   PubMed Web of Science ®Google Scholar
• Douvdevani A, Huleihel M, Zoller M, Segal S, Apte RN. Reduced tumorigenicity of fibrosarcomas which constitutively generate IL-1 alpha either spontaneously or following IL-1 alpha gene transfer. Int J Cancer 1992; 51:822-30; PMID:1612788; http://dx.doi.org/10.1002/ijc.2910510526
   PubMed Web of Science ®Google Scholar
• Apte RN, Douvdevani A, Zoller M, White RM, Dvorkin T, Shimoni N, Fima E, Hacham M, Huleihel M, Benharroch D et al. Cytokine-induced tumor immunogenicity: endogenous interleukin-1 alpha expressed by fibrosarcoma cells confers reduced tumorigenicity. Immunol Lett 1993; 39:45-52; PMID:8144190; http://dx.doi.org/10.1016/0165-2478(93)90163-V
   PubMed Web of Science ®Google Scholar
• Voronov E, Weinstein Y, Benharroch D, Cagnano E, Ofir R, Dobkin M, White RM, Zoller M, Barak V, Segal S et al. Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1alpha expression. Cancer Res 1999; 59:1029-35; PMID:10070959
   PubMed Web of Science ®Google Scholar
• Dvorkin T, Song X, Argov S, White RM, Zoller M, Segal S, Dinarello CA, Voronov E, Apte RN. Immune phenomena involved in the in vivo regression of fibrosarcoma cells expressing cell-associated IL-1alpha. J Leukoc Biol 2006; 80:96-106; PMID:16707560; http://dx.doi.org/10.1189/jlb.0905509
   PubMed Web of Science ®Google Scholar
• Danforth DN Jr, Sgagias MK. Interleukin-1 alpha and interleukin-6 act additively to inhibit growth of MCF-7 breast cancer cells in vitro. Cancer Res 1993; 53:1538-45; PMID:8453620
   PubMed Web of Science ®Google Scholar
• Sgagias MK, Kasid A, Danforth DN, Jr. Interleukin-1 alpha and tumor necrosis factor-alpha (TNF alpha) inhibit growth and induce TNF messenger RNA in MCF-7 human breast cancer cells. Mol Endocrinol 1991; 5:1740-7; PMID:1779975; http://dx.doi.org/10.1210/mend-5-11-1740
   PubMed Web of Science ®Google Scholar
• Morinaga Y, Hayashi H, Takeuchi A, Onozaki K. Antiproliferative effect of interleukin 1 (IL-1) on tumor cells: G0-G1 arrest of a human melanoma cell line by IL-1. Biochem Biophys Res Commun 1990; 173:186-92; PMID:2256913; http://dx.doi.org/10.1016/S0006-291X(05)81039-3
   PubMed Web of Science ®Google Scholar
• Maund SL, Barclay WW, Hover LD, Axanova LS, Sui G, Hipp JD, Fleet JC, Thorburn A, Cramer SD. Interleukin-1alpha mediates the antiproliferative effects of 1,25-dihydroxyvitamin D3 in prostate progenitor/stem cells. Cancer Res 2011; 71:5276-86; PMID:21653679; http://dx.doi.org/10.1158/0008-5472.CAN-10-2160
   PubMed Web of Science ®Google Scholar
• Maund SL, Shi L, Cramer SD. A role for interleukin-1 alpha in the 1,25 dihydroxyvitamin D3 response in mammary epithelial cells. PLoS One 2013; 8:e81367; PMID:24244740; http://dx.doi.org/10.1371/journal.pone.0081367
   PubMed Web of Science ®Google Scholar
• Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992; 12:954-61; PMID:1312220; http://dx.doi.org/10.1128/MCB.12.3.954
   PubMed Web of Science ®Google Scholar
• Marcotte R, Muller WJ. Signal transduction in transgenic mouse models of human breast cancer – implications for human breast cancer. J Mammary Gland Biol Neoplasia 2008; 13:323-35; PMID:18651209; http://dx.doi.org/10.1007/s10911-008-9087-3
   PubMed Web of Science ®Google Scholar
• Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007; 8:R76; PMID:17493263; http://dx.doi.org/10.1186/gb-2007-8-5-r76
   PubMed Web of Science ®Google Scholar
• Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A et al. Proteomics. Tissue-based map of the human proteome. Science 2015; 347:1260419; PMID:25613900; http://dx.doi.org/10.1126/science.1260419
   PubMed Web of Science ®Google Scholar
• Mikaelian I, Hovick M, Silva KA, Burzenski LM, Shultz LD, Ackert-Bicknell CL, Cox GA, Sundberg JP. Expression of terminal differentiation proteins defines stages of mouse mammary gland development. Vet Pathol 2006; 43:36-49; PMID:16407485; http://dx.doi.org/10.1354/vp.43-1-36
   PubMed Web of Science ®Google Scholar
• Verderame M, Alcorta D, Egnor M, Smith K, Pollack R. Cytoskeletal F-actin patterns quantitated with fluorescein isothiocyanate-phalloidin in normal and transformed cells. Proc Natl Acad Sci USA 1980; 77:6624-8; PMID:6256751; http://dx.doi.org/10.1073/pnas.77.11.6624
   PubMed Web of Science ®Google Scholar
• Francia G, Cruz-Munoz W, Man S, Xu P, Kerbel RS. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer 2011; 11:135-41; PMID:21258397; http://dx.doi.org/10.1038/nrc3001
   PubMed Web of Science ®Google Scholar
• DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, Coussens LM. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009; 16:91-102; PMID:19647220; http://dx.doi.org/10.1016/j.ccr.2009.06.018
   PubMed Web of Science ®Google Scholar
• Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001; 193:727-40; PMID:11257139; http://dx.doi.org/10.1084/jem.193.6.727
   PubMed Web of Science ®Google Scholar
• Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011; 475:222-5; PMID:21654748; http://dx.doi.org/10.1038/nature10138
   PubMed Web of Science ®Google Scholar
• DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011; 1:54-67; PMID:22039576; http://dx.doi.org/10.1158/2159-8274.CD-10-0028
   PubMed Web of Science ®Google Scholar
• Szasz AM, Lanczky A, Nagy A, Forster S, Hark K, Green JE, Boussioutas A, Busuttil R, Szabó A, Győrffy B. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget 2016; 7(31):49322-33; PMID:27384994; http://dx.doi.org/10.18632/oncotarget.10337
   PubMed Web of Science ®Google Scholar
• Rider P, Carmi Y, Guttman O, Braiman A, Cohen I, Voronov E, White MR, Dinarello CA, Apte RN. IL-1alpha and IL-1beta recruit different myeloid cells and promote different stages of sterile inflammation. J Immunol 2011; 187:4835-43; PMID:21930960; http://dx.doi.org/10.4049/jimmunol.1102048
   PubMed Web of Science ®Google Scholar
• Gross O, Yazdi AS, Thomas CJ, Masin M, Heinz LX, Guarda G, Quadroni M, Drexler SK, Tschopp J. Inflammasome activators induce interleukin-1alpha secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity 2012; 36:388-400; PMID:22444631; http://dx.doi.org/10.1016/j.immuni.2012.01.018
   PubMed Web of Science ®Google Scholar
• Derksen PW, Liu X, Saridin F, van der Gulden H, Zevenhoven J, Evers B, van Beijnum JR, Griffioen AW, Vink J, Krimpenfort P et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 2006; 10:437-49; PMID:17097565; http://dx.doi.org/10.1016/j.ccr.2006.09.013
   PubMed Web of Science ®Google Scholar
• Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau CS, Verstegen NJ, Ciampricotti M, Hawinkels LJ, Jonkers J et al. IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature 2015; 522:345-8; PMID:25822788; http://dx.doi.org/10.1038/nature14282
   PubMed Web of Science ®Google Scholar
• Barak V, Nisman B, Polliack A, Vannier E, Dinarello CA. Correlation of serum levels of interleukin-1 family members with disease activity and response to treatment in hairy cell leukemia. Eur Cytokine Netw 1998; 9:33-9; PMID:9613675
   PubMed Web of Science ®Google Scholar
• Fujiwaki R, Iida K, Nakayama K, Kanasaki H, Hata K, Katabuchi H, Okamura H, Miyazaki K. Clinical significance of interleukin-1 receptor antagonist in patients with cervical carcinoma. Gynecol Oncol 2003; 89:77-83; PMID:12694657; http://dx.doi.org/10.1016/S0090-8258(02)00154-3
   PubMed Web of Science ®Google Scholar
• Mustea A, Pirvulescu C, Konsgen D, Braicu EI, Yuan S, Sun P, Lichtenegger W, Sehouli J. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer. Cytokine 2008; 42:77-84; PMID:18329282; http://dx.doi.org/10.1016/j.cyto.2008.01.011
   PubMed Web of Science ®Google Scholar
• Kaminska J, Kowalska MM, Nowacki MP, Chwalinski MG, Rysinska A, Fuksiewicz M. CRP, TNF-alpha, IL-1ra, IL-6, IL-8 and IL-10 in blood serum of colorectal cancer patients. Pathol Oncol Res 2000; 6:38-41; PMID:10749586; http://dx.doi.org/10.1007/BF03032656
   PubMedGoogle Scholar
• Ebrahimi B, Tucker SL, Li D, Abbruzzese JL, Kurzrock R. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer 2004; 101:2727-36; PMID:15526319; http://dx.doi.org/10.1002/cncr.20672
   PubMed Web of Science ®Google Scholar
• Lv M, Xiaoping X, Cai H, Li D, Wang J, Fu X, Yu F, Sun M, Lv Z. Cytokines as prognostic tool in breast carcinoma. Front Biosci (Landmark Ed) 2011; 16:2515-26; PMID:21622192; http://dx.doi.org/10.2741/3869
   PubMed Web of Science ®Google Scholar
• Ricote M, Garcia-Tunon I, Bethencourt FR, Fraile B, Paniagua R, Royuela M. Interleukin-1 (IL-1alpha and IL-1beta) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma. Cancer 2004; 100:1388-96; PMID:15042672; http://dx.doi.org/10.1002/cncr.20142
   PubMed Web of Science ®Google Scholar
• Iwagaki H, Hizuta A, Tanaka N. Interleukin-1 receptor antagonists and other markers in colorectal cancer patients. Scand J Gastroenterol 1997; 32:577-81; PMID:9200291; http://dx.doi.org/10.3109/00365529709025103
   PubMed Web of Science ®Google Scholar
• Ito H, Miki C. Profile of circulating levels of interleukin-1 receptor antagonist and interleukin-6 in colorectal cancer patients. Scand J Gastroenterol 1999; 34:1139-43; PMID:10582766; http://dx.doi.org/10.1080/003655299750024959
   PubMed Web of Science ®Google Scholar
• Parekh DJ, Ankerst DP, Baillargeon J, Higgins B, Platz EA, Troyer D, Hernandez J, Leach RJ, Lokshin A, Thompson IM. Assessment of 54 biomarkers for biopsy-detectable prostate cancer. Cancer Epidemiol Biomark Prev 2007; 16:1966-72; PMID:17932343; http://dx.doi.org/10.1158/1055-9965.EPI-07-0302
   PubMed Web of Science ®Google Scholar
• Niedzwiecki S, Stepien T, Kuzdak K, Stepien H, Krupinski R, Seehofer D, Rayes N, Ulrich F. Serum levels of interleukin-1 receptor antagonist (IL-1ra) in thyroid cancer patients. Langenbecks Arch Surg 2008; 393:275-80; PMID:18064485; http://dx.doi.org/10.1007/s00423-007-0251-9
   PubMed Web of Science ®Google Scholar
• Gherardi RK, Belec L, Soubrier M, Malapert D, Zuber M, Viard JP, Intrator L, Degos JD, Authier FJ. Overproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome. Blood 1996; 87:1458-65; PMID:8608236
   PubMed Web of Science ®Google Scholar
• Poch B, Lotspeich E, Ramadani M, Gansauge S, Beger HG, Gansauge F. Systemic immune dysfunction in pancreatic cancer patients. Langenbecks Arch Surg 2007; 392:353-8; PMID:17235586; http://dx.doi.org/10.1007/s00423-006-0140-7
   PubMed Web of Science ®Google Scholar
• Qian B, Deng Y, Im JH, Muschel RJ, Zou Y, Li J, Lang RA, Pollard JW. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS One 2009; 4:e6562; PMID:19668347; http://dx.doi.org/10.1371/journal.pone.0006562
   PubMed Web of Science ®Google Scholar
• Dagenais M, Dupaul-Chicoine J, Champagne C, Skeldon A, Morizot A, Saleh M. A critical role for cellular inhibitor of protein 2 (cIAP2) in colitis-associated colorectal cancer and intestinal homeostasis mediated by the inflammasome and survival pathways. Mucosal Immunol 2016; 9:146-58; PMID:26037070; http://dx.doi.org/10.1038/mi.2015.46
   PubMed Web of Science ®Google Scholar